Document is current
Any future updates will be listed below
-
Authors
Sacks, Chana A.
North, Crystal M.
Wolf, Molly
Dougan, Michael
Campbell, Kieran R
Moggridge, Jason
Fralick, Michael https://orcid.org/0000-0002-2082-2445
-
Funding
Funding for this research was provided by:
Sinai Research Fund
- License Information
-
More Information
Article History
Received: 8 April 2021
Accepted: 24 September 2021
First Online: 9 November 2021
Declarations
:
: Drs. Sacks, North, Wolf, and Campbell report no conflicts of interest. Dr. Dougan has received consulting fees from Tillotts Pharma, Partner Therapeutics, ORIC pharmaceuticals, and Moderna; research funding from Novartis and Eli Lilly and is a member of the scientific advisory board of Neoleukin Therapeutics. Dr. Fralick is a consultant for ProofDx (previously Pine Trees Health), a start-up company developing a CRISPR-based diagnostic test for COVID-19.
Free to read: This content has been made available to all.
